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TRANSLATIONAL PERSPECTIVE
Almost four decades since its initial discovery in brain (Schulman
and Greengard, 1978), the multifunctional Ca2+ and calmodulin-
dependent protein kinase II (CaMKII) has now emerged as a key
signaling molecule in the heart. The isoform that predominates in
heart, CaMKIIδ, directly regulates expression and function of sev-
eral of the main cardiac ion channels and Ca2+ handling proteins
(Bers and Grandi, 2009). CaMKII-dependent effects are thought
to orchestrate many of the electrophysiologic and contractile
adaptations to common cardiac stressors, such as rapid pacing,
adrenergic stimulation, and oxidative challenge. In the context of
disease, CaMKII has been shown to contribute to a remarkably
wide variety of cardiac pathologies, including myocardial hyper-
trophy, ischemia, heart failure (HF), and arrhythmia. CaMKII
expression is increased in patients with HF (Hoch et al., 1999),
and elevated CaMKII expression and activity have been impli-
cated in the transition to HF (Zhang et al., 2003). Indeed, inhibit-
ing CaMKII appears to reduce arrhythmias and pathological
signaling, which makes this kinase a promising new therapeutic
target (Anderson et al., 2011).
OVERVIEW OF THE RESEARCH TOPIC
This series reviews the molecular physiology of CaMKII and dis-
cusses the impact of CaMKII on heart function. The subjects
were chosen to summarize the current state of our knowledge of
various aspects of CaMKII-mediated control of myocyte physiol-
ogy, with in-depth focused reviews by recognized leaders in these
areas.
To start off, a group of articles examines the biochemistry of
CaMKII activation and the pharmacology of its inhibitors. Recent
efforts to characterize the individual pathways of CaMKII acti-
vation in the heart are reviewed. These studies improved our
understanding of the downstream pathological consequences of
these specific pathways (Erickson, 2014). Indeed, the promise of
CaMKII inhibition for simultaneous prevention of HF progres-
sion and development of arrhythmias justifies the development
of more specific CaMKII inhibitors that will further both basic
research studies and drug development (Westenbrink et al., 2013).
Thus, the kinase structure and possible sites for its inhibition
(Pellicena and Schulman, 2014) are illustrated. It is also becoming
clear that design of therapeutic intervention requires an improved
understanding of the specific roles and function of the CaMKIIδ
subtypes, δB and δC, as discussed by Gray and Heller Brown
(2014).
A second group of articles reviews the large body of work
describing CaMKII-specific interaction with its numerous intra-
cellular targets, many of which play important roles in modu-
lating cardiac excitation contraction coupling (ECC). CaMKII
involvement at multiple levels in ECC indicates that it is an
important modulator of both electrophysiological and contrac-
tile properties in the heart. Active CaMKII phosphorylates several
Ca2+ handling proteins including ryanodine receptors (RyR2)
(Camors and Valdivia, 2014), phospholamban (Mattiazzi and
Kranias, 2014), and L-type Ca2+ channels (Bers and Morotti,
2014). In addition, non-Ca2+ transporters such as sarcolem-
mal Na+ (Grandi and Herren, 2014) and K+ (Mustroph
et al., 2014) channels are regulated by CaMKII. This in turn
influences myocyte Ca2+ regulation and also confers further
Ca2+-dependence to a variety of electrophysiological processes.
In combination these effects create a complex and non-linear
feedback system that necessitates quantitative computational
approaches. As such, multiscale models have played an impor-
tant role in advancing our understanding of CaMKII function in
cardiac ECC, particularly by being able to both reconstruct the
details of local signaling events within the cardiac dyad, and pre-
dict their functional consequences at the level of the whole cell
(Greenstein et al., 2014). CaMKII also regulates Ca2+ handling
proteins that are thought to contribute relatively little to ECC, the
best example of which is the inositol 1,4,5-trisphosphate receptor
(IP3R), as reviewed by Camors and Valdivia (2014). This regula-
tory role is thought to be key in modulating IP3R-mediated Ca2+
release in the regulation of cytosolic and nuclear Ca2+ signals
(Hohendanner et al., 2014). These mechanisms are suspected to
be involved in coupling cytosolic and SR Ca2+ handling to adap-
tive transcriptional and epigenetic processes. Indeed, in addition
to the above-mentioned acute effects due to phosphorylation of
cytosolic proteins, CaMKII has been shown to influence chronic
physiological and pathological processes, particularly those con-
tributing to the ventricular remodeling that leads to HF (Kreusser
and Backs, 2014).
Finally, the integrative role of this enzyme in cardiac phys-
iology and disease is discussed. As described above, the multi-
functional nature of CaMKII causes this integration to be very
challenging, and the development of detailed multiscale com-
putational models has greatly improved our ability to describe
howmolecular actions can impact tissue and organ function. The
review by Onal et al. (2014) dissects how these systems biology
approaches have contributed to linking CaMKII activity in single
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myocytes to observable tissue-level arrhythmogenic outcomes
in cardiac disease. Experimental disease models that incorpo-
rate CaMKII overexpression clearly demonstrate a link between
its excessive activity and arrhythmias associated with congen-
ital and acquired heart disease. Vincent et al. (2014) review
CaMKII involvement in both types of disease, and argue that the
importance of CaMKII phosphorylation at RyR2 across a vari-
ety of disease models suggests that this molecular interaction
may be a point of mechanistic convergence in many forms of
cardiac arrhythmia. In addition to its abundantly studied ven-
tricular consequences, such as in HF and ischemia/reperfusion
challenge (Bell et al., 2014), CaMKII has emerged as a key
determinant of sinoatrial node dysfunction (as well as a cen-
tral regulator of physiological sinoatrial node responses) (Wu
and Anderson, 2014; Yaniv and Maltsev, 2014). Recently, a sig-
nificant effort has also been invested in describing the role
played by CaMKII in atrial fibrillation, where the many actions
of CaMKII are superimposed upon the unique electrophys-
iologic and structural characteristics of the diseased atrium
(Heijman et al., 2014).
CONCLUSIONS AND FUTURE DIRECTIONS
CaMKII is an abundant signaling molecule in myocardium,
where it integrates and transduces cellular Ca2+ signals into phys-
iological responses in heart. Under various pathological stresses,
CaMKII hyperactivity appears to be an important component
of disease signaling. However, in the context of complex cardiac
disease, such as HF, multiple signaling pathways are likely to be
altered, many of which might crosstalk with CaMKII signaling.
Thus, the interplay of various mechanisms of CaMKII activation,
particularly during the development of cardiovascular diseases,
is an important open avenue of investigation. As a complicating
factor, CaMKII itself contributes to the regulation of intracellular
signaling processes, such as mitochondrial function (Joiner and
Koval, 2014), thus forming potential feedback loops leading to
further CaMKII activation.
Recent findings that CaMKII inhibition ameliorates HF
and suppresses arrhythmias suggest that developing specific
CaMKII inhibitory drugs may be a new therapeutic approach to
these diseases. However, current pharmacological tools are lim-
ited. Development of new inhibitors (Pellicena and Schulman,
2014) will enable preclinical proof-of-concept tests and clin-
ical development of successful lead compounds, as well as
improved research tools to more accurately examine and extend
knowledge of the role of CaMKII in cardiac health and
disease.
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